TELA Bio (TELA) stock price, revenue, and financials

TELA Bio market cap is $229.3 m, and annual revenue was $15.45 m in FY 2019

$229.3 M

TELA Mkt cap, 22-Sept-2020

$3.5 M

TELA Bio Revenue Q2, 2020
TELA Bio Net income (Q2, 2020)-6.1 M
TELA Bio EBIT (Q2, 2020)-5.2 M
TELA Bio Cash, 30-Jun-202085.5 M
TELA Bio EV174.4 M

TELA Bio Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

4.2m8.3m15.4m

Revenue growth, %

95%

Cost of goods sold

1.7m5.3m

Gross profit

2.5m2.9m

Gross profit Margin, %

60%36%

Sales and marketing expense

8.7m13.6m18.1m

R&D expense

5.8m4.3m4.2m

General and administrative expense

5.0m4.9m6.2m

Operating expense total

19.5m22.9m28.4m

EBIT

(16.9m)(17.8m)(19.2m)

EBIT margin, %

(399%)(215%)(124%)

Interest expense

4.6m1.8m

Net Income

(21.3m)(21.1m)(22.4m)

Quarterly

TELA Bio Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

11.3m17.3m45.3m

Accounts Receivable

757.0k1.3m2.8m

Prepaid Expenses

429.0k330.0k2.3m

Inventories

1.8m4.3m4.6m

Current Assets

14.3m23.3m64.3m

PP&E

1.2m758.0k677.0k

Goodwill

2.9m

Total Assets

15.5m27.2m67.9m

Accounts Payable

1.5m3.4m3.2m

Short-term debt

905.0k

Current Liabilities

6.1m9.6m6.7m

Long-term debt

3.6m29.7m

Total Debt

4.5m29.7m

Total Liabilities

12.4m40.9m37.0m

Common Stock

7.0k7.0k11.0k

Preferred Stock

111.3m124.2m

Additional Paid-in Capital

198.8m

Retained Earnings

(108.2m)(137.9m)(167.9m)

Total Equity

3.2m(13.7m)31.0m

Debt to Equity Ratio

1.4 x-2.2 x

Debt to Assets Ratio

0.3 x1.1 x

Financial Leverage

4.9 x-2 x2.2 x

Quarterly

USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

15.8m10.7m41.4m85.5m

Accounts Receivable

1.9m2.3m2.0m2.6m

Prepaid Expenses

384.0k365.0k1.8m1.5m

Inventories

4.6m4.3m4.8m4.6m

Current Assets

22.8m17.6m55.3m94.1m

PP&E

712.0k716.0k693.0k678.0k

Goodwill

3.0m

Total Assets

26.6m23.1m58.8m97.6m

Accounts Payable

2.1m1.7m1.4m948.0k

Current Liabilities

7.6m6.3m4.2m3.6m

Long-term debt

30.0m30.4m30.5m

Total Debt

30.0m30.4m30.5m

Total Liabilities

39.3m38.1m34.6m34.1m

Common Stock

7.0k11.0k14.0k

Preferred Stock

141.1m

Additional Paid-in Capital

199.3m244.5m

Retained Earnings

(153.7m)(160.4m)(175.1m)(181.2m)

Total Equity

(12.7m)(160.4m)24.2m63.4m

Debt to Equity Ratio

-2.4 x

Debt to Assets Ratio

1.1 x

Financial Leverage

-2.1 x-0.1 x2.4 x1.5 x

TELA Bio Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(21.3m)(21.1m)(22.4m)

Depreciation and Amortization

761.0k463.0k278.0k

Accounts Receivable

(578.0k)(541.0k)(1.5m)

Inventories

(1.8m)

Accounts Payable

(114.0k)(62.0k)(773.0k)

Cash From Operating Activities

(16.4m)(19.9m)(25.5m)

Purchases of PP&E

(114.0k)(62.0k)(197.0k)

Cash From Investing Activities

(101.0k)(1.6m)(12.0m)

Short-term Borrowings

(5.7m)

Long-term Borrowings

(13.0m)

Cash From Financing Activities

26.3m27.4m65.5m

Net Change in Cash

9.9m5.9m28.0m

Interest Paid

329.0k1.1m3.1m

Quarterly

USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(10.9m)(11.2m)(15.9m)(7.2m)(13.3m)

Depreciation and Amortization

309.0k135.0k206.0k56.0k95.0k

Accounts Receivable

(475.0k)(599.0k)(983.0k)781.0k238.0k

Inventories

(1.0m)(617.0k)(750.0k)

Accounts Payable

324.0k(1.3m)(2.5m)(1.3m)(2.1m)

Cash From Operating Activities

(10.8m)(13.0m)(18.3m)(7.3m)(13.7m)

Purchases of PP&E

(31.0k)(89.0k)(164.0k)(68.0k)(96.0k)

Cash From Investing Activities

(31.0k)(589.0k)(2.7m)3.9m9.2m

Short-term Borrowings

(1.5m)

Long-term Borrowings

(5.0m)

Cash From Financing Activities

4.8m12.2m14.4m(514.0k)44.6m

Net Change in Cash

(6.1m)(1.4m)(6.6m)(3.9m)40.2m

Interest Paid

102.0k2.3m745.0k1.5m

TELA Bio Ratios

USDFY, 2017

Revenue/Employee

95.5k

Debt/Equity

1.4 x

Debt/Assets

0.3 x

Financial Leverage

4.9 x

TELA Bio Operating Metrics

Jun, 2019

Patients Enrolled

32

Surgeons Collaborated

100